Company intelligence / Profile preview

Pinteon Therapeutics

Newton Center, Massachusetts, United States3mediaweb.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

PNT001, their lead antibody, completed a Phase 1 safety study in healthy adults showing it was well-tolerated at doses that may provide therapeutic effect. A Phase 1 study in acute traumatic brain injury was terminated for non-safety reasons after enrolling only one patient. The company had planned a Phase 1b/Phase 2 study in Alzheimer's disease patients by the end of 2021.

Therapeutic areas: Neurology
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

1 asset

PNT001

Partnerships

Advanced Technology International (ATI)U.S. Department of Defense

Beyond the preview

Go deeper on Pinteon Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pinteon Therapeutics.

Explore the full profile